Latest press releases http://www.astrazeneca.com 1277293175128 Tue, 30 Sep 2014 22:53:36 +0100 Tue, 30 Sep 2014 22:53:36 +0100 AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid. http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-updates-on-progress-of-oncology-pipeline-at-esmo-2014-congress 1285588699378 Sat, 27 Sep 2014 11:45:00 +0100 MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). http://www.astrazeneca.com/Media/Press-releases/Article/20142609--moventig-naloxegol-receives-positive-CHMP-opinion-in-the-EU-for-the-treatment-of-adults-with-opioid-induced-constipation 1285588692475 Fri, 26 Sep 2014 11:00:00 +0100 IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update* to the European label for IRESSA® (gefitinib). http://www.astrazeneca.com/Media/Press-releases/Article/20142609--iressa-receives-chmp-positive-opinion-to-include-blood-based-diagnostic-testing-in-european-label 1285588692522 Fri, 26 Sep 2014 06:17:04 +0100 MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK. http://www.astrazeneca.com/Media/Press-releases/Article/20142409--medimmune-and-cancer-research-uk-establish-joint-laboratory-develop-biologic-medicines 1285588686034 Thu, 25 Sep 2014 06:32:00 +0100 Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes AstraZeneca today announced 28-week results from DURATION-NEO-1 http://www.astrazeneca.com/Media/Press-releases/Article/09192014--study-showed-astrazenecas-exenatide 1285588664711 Fri, 19 Sep 2014 12:10:53 +0100 FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. http://www.astrazeneca.com/Media/Press-releases/Article/20140916--fda-approves-movantik-tablets 1285588642685 Tue, 16 Sep 2014 16:23:34 +0100 AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease AstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. http://www.astrazeneca.com/Media/Press-releases/Article/astrazeneca-and-lilly-announce-alliance 1285588636077 Tue, 16 Sep 2014 07:05:00 +0100 AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes AstraZeneca today announced that 29 abstracts covering a range of data from the company’s research and development in diabetes have been accepted for presentation at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, 15-19 September 2014. http://www.astrazeneca.com/Media/Press-releases/Article/20141010--astrazeneca-to-present-research 1285588607132 Wed, 10 Sep 2014 04:42:38 +0100 Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine AstraZeneca today announced that The Lancet Respiratory Medicine has published encouraging safety and efficacy data from a Phase IIa study evaluating its novel investigational monoclonal antibody benralizumab in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazeneca.com/Media/Press-releases/Article/08092014--benralizumab-phase-ii-copd-study-published-in-the-lan 1285588594036 Mon, 8 Sep 2014 06:19:20 +0100 New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients AstraZeneca today announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. The data will be presented during the European Society of Cardiology congress taking place between 30 August and 3 September 2014 in Barcelona. http://www.astrazeneca.com/Media/Press-releases/Article/01092014--New-data-indicates-Brilinta-Brilique-has-the-flexibility-to-be-initiated-pre-hospital-or-in-hospital-in-STEMI-patients 1285588558642 Mon, 1 Sep 2014 07:00:00 +0100 AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests AstraZeneca today announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio. In the first instance, AstraZeneca intends to apply Illumina’s cutting-edge technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. This is expected to be one of the first NGS-based companion diagnostic tests for a novel drug in the world, and its application could speed the clinical trial process. http://www.astrazeneca.com/Media/Press-releases/Article/20140821--astrazeneca-announces-partnership-with-illumina 1285588478510 Thu, 21 Aug 2014 06:26:23 +0100 AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI) AstraZeneca today announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections. http://www.astrazeneca.com/Media/Press-releases/Article/20140819--astrazeneca-announces-positive-topline 1285588463154 Tue, 19 Aug 2014 07:00:42 +0100